RU2017135552A - Глутамат оксалоацетат трансаминаза 1 (got1), препараты и способы их получения и применения - Google Patents

Глутамат оксалоацетат трансаминаза 1 (got1), препараты и способы их получения и применения Download PDF

Info

Publication number
RU2017135552A
RU2017135552A RU2017135552A RU2017135552A RU2017135552A RU 2017135552 A RU2017135552 A RU 2017135552A RU 2017135552 A RU2017135552 A RU 2017135552A RU 2017135552 A RU2017135552 A RU 2017135552A RU 2017135552 A RU2017135552 A RU 2017135552A
Authority
RU
Russia
Prior art keywords
got1
fusion protein
sumo
polypeptide
preparation
Prior art date
Application number
RU2017135552A
Other languages
English (en)
Russian (ru)
Other versions
RU2017135552A3 (cg-RX-API-DMAC10.html
Inventor
Давид МИРЕЛЬМАН
Ахарон РАБИНКОВ
Анжела РУБАН
Гил ЙОНА
Эли ХАЗУМ
Владас БУМЕЛИС
Нериюс МАКАУСКАС
Сауле СУДЖИУВИЭНЕ
Елена НАРМОНТАЙТЕ
Original Assignee
Иеда Рисеч Энд Девелопмент Ко. Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иеда Рисеч Энд Девелопмент Ко. Лтд. filed Critical Иеда Рисеч Энд Девелопмент Ко. Лтд.
Publication of RU2017135552A publication Critical patent/RU2017135552A/ru
Publication of RU2017135552A3 publication Critical patent/RU2017135552A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/303—Extraction; Separation; Purification by precipitation by salting out
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1096—Transferases (2.) transferring nitrogenous groups (2.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01001—Aspartate transaminase (2.6.1.1), i.e. aspartate-aminotransferase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
RU2017135552A 2015-03-31 2016-03-31 Глутамат оксалоацетат трансаминаза 1 (got1), препараты и способы их получения и применения RU2017135552A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562140492P 2015-03-31 2015-03-31
US62/140,492 2015-03-31
PCT/IL2016/050346 WO2016157190A1 (en) 2015-03-31 2016-03-31 Glutamate oxaloacetate transaminase 1 (got1), preparations and methods of generating same and uses thereof

Publications (2)

Publication Number Publication Date
RU2017135552A true RU2017135552A (ru) 2019-04-30
RU2017135552A3 RU2017135552A3 (cg-RX-API-DMAC10.html) 2019-07-24

Family

ID=55795016

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017135552A RU2017135552A (ru) 2015-03-31 2016-03-31 Глутамат оксалоацетат трансаминаза 1 (got1), препараты и способы их получения и применения

Country Status (11)

Country Link
US (1) US20180071369A1 (cg-RX-API-DMAC10.html)
EP (1) EP3277308A1 (cg-RX-API-DMAC10.html)
JP (1) JP2018511325A (cg-RX-API-DMAC10.html)
KR (1) KR20170132293A (cg-RX-API-DMAC10.html)
CN (1) CN107771217A (cg-RX-API-DMAC10.html)
AU (1) AU2016242298A1 (cg-RX-API-DMAC10.html)
BR (1) BR112017021016A2 (cg-RX-API-DMAC10.html)
CA (1) CA2979309A1 (cg-RX-API-DMAC10.html)
HK (1) HK1243329A1 (cg-RX-API-DMAC10.html)
RU (1) RU2017135552A (cg-RX-API-DMAC10.html)
WO (1) WO2016157190A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018229764A1 (en) 2017-06-13 2018-12-20 Yeda Research And Development Co. Ltd. Treatment of advanced or progressive multiple sclerosis
RU2712193C1 (ru) * 2018-07-27 2020-01-24 Общество с ограниченной ответственностью научно-технический центр "БиоКлиникум" (ООО НТЦ "БиоКлиникум") Способ лечения поражения нервной системы с помощью рекомбинантной глутаматоксалоацетаттрансаминазы
US11740211B2 (en) * 2020-01-31 2023-08-29 Waters Technologies Corporation LC/MS adduct mitigation by vapor deposition coated surfaces
CN116143898B (zh) * 2023-01-30 2026-03-24 翌圣生物科技(上海)股份有限公司 骨形态发生蛋白bmp-2重组蛋白、编码基因及其原核表达方法
CN118147225A (zh) * 2024-03-25 2024-06-07 华中农业大学 黄颡鱼去sumo化修饰体系及其构建方法和应用
WO2026139625A1 (en) 2024-12-26 2026-07-02 Alternative Gene Expression S.L. Glutamate-oxaloacetate transaminase (got1) – fc (fragment crystallizable) fusion proteins

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
DE60318014T2 (de) * 2002-01-07 2008-11-27 Lifesensors, Inc. Verfahren und zusammensetzungen für die proteinexpression und reinigung
CA2494348C (en) * 2002-08-01 2014-04-08 Yeda Research And Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
GB0315248D0 (en) * 2003-06-30 2003-08-06 Hoffmann La Roche HCV regulated protein expression
WO2006069610A2 (en) * 2004-07-02 2006-07-06 Metanomics Gmbh Process for the production of fine chemicals
EP2096177A3 (en) * 2004-12-17 2010-01-13 Metanomics GmbH Process for the production of lutein
EP1836214A4 (en) 2004-12-30 2009-01-21 Lifesensors Inc COMPOSITIONS, METHODS, AND KITS FOR IMPROVING PROTEIN EXPRESSION, SOLUBILITY, AND ISOLATION
CA2670014A1 (en) * 2006-11-22 2008-11-20 Emory University Production of anti-microbial peptides
CA2674304C (en) * 2006-12-29 2016-02-23 Lifesensors, Inc. Methods and compositions for enhanced protein expression and purification
ES2534936T3 (es) * 2010-08-02 2015-04-30 Ratiopharm Gmbh Método para producir y purificar una sialiltransferasa soluble activa
WO2012159782A1 (en) * 2011-05-24 2012-11-29 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune High affinity sumo traps

Also Published As

Publication number Publication date
CA2979309A1 (en) 2016-10-06
RU2017135552A3 (cg-RX-API-DMAC10.html) 2019-07-24
HK1243329A1 (zh) 2018-07-13
JP2018511325A (ja) 2018-04-26
US20180071369A1 (en) 2018-03-15
CN107771217A (zh) 2018-03-06
WO2016157190A1 (en) 2016-10-06
KR20170132293A (ko) 2017-12-01
BR112017021016A2 (pt) 2018-07-03
AU2016242298A1 (en) 2017-10-19
EP3277308A1 (en) 2018-02-07

Similar Documents

Publication Publication Date Title
IL278014B2 (en) Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
HRP20200871T1 (hr) Izmjenjeni rsv f proteini i postupci njihove uporabe
FI3461261T3 (fi) Yksiketjuisen vaihtelevan fragmentin sisältäviä cd3:a sitovia proteiineja
HRP20230991T1 (hr) Inzulin-fc fuzijski proteini ultradugog djelovanja i metode uporabe
JP2015212284A5 (cg-RX-API-DMAC10.html)
RU2011137030A (ru) Способы очистки малых модулярных иммунофармацевтических белков
RU2018113505A (ru) Il-8-связывающие антитела и их применения
JP2015524403A5 (cg-RX-API-DMAC10.html)
JP2017514522A5 (cg-RX-API-DMAC10.html)
JP2021517805A5 (cg-RX-API-DMAC10.html)
HRP20171694T1 (hr) Novi pripravci i postupci
ZA202503137B (en) Truncated respiratory syncytial virus f protein and use thereof
RU2016108976A (ru) С5-связующие полипептиды
EA201300056A1 (ru) Полипептид с активностью ацетилксиланэстеразы и его применения
HRP20250701T1 (hr) Himerni protein papiloma virusa l1
JP2018511325A5 (cg-RX-API-DMAC10.html)
JP2014503216A5 (cg-RX-API-DMAC10.html)
JP2019505567A5 (cg-RX-API-DMAC10.html)
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
RU2013111675A (ru) Рекомбинантный fc-гибридный белок пятого домена фибронектина типа iii dcc
EA201300059A1 (ru) Полипептид, обладающий активностью сволленина, и его применение
US20250215050A1 (en) Compositions and methods for purifying biological fluids
JP2017533182A5 (cg-RX-API-DMAC10.html)
RU2018141714A (ru) Слитый белок, содержащий вариант CCL3, и его применение
JP2019503171A5 (cg-RX-API-DMAC10.html)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200210